|
An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis |
Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Hari M, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Hari M, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technology Assessment 2012; 16(7): 1-186 Authors' conclusions Study found treatment effect of intravenous immunoglobulin on mortality for patients with severe sepsis is borderline significant with a large degree of heterogeneity in the treatment effect between individual studies. Indexing Status Subject indexing assigned by CRD MeSH Humans; Immunoglobulins, Intravenous; Randomized Controlled Trials as Topic; Sepsis; Shock, Septic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010000298 Date abstract record published 21/04/2010 |
|
|
|